Table 3.

Ongoing LAI-ART Clinical Trials^a

Alternative Drug Injection Locations
NCT04371380	IM injections of CAB/RPV-LA administrated in the vastus lateralis muscle—Phase 1
NCT04484337	IM injections of CAB-LA administered IM (gluteal and lateral thigh) or SC (abdominal)—Phase 1
Special Populations
NCT03635788	AIDS Clinical Trials Group Study A5359: LATITUDE (Long-Acting Therapy to Improve Treatment SUccess in Daily LifE)—Randomized trial evaluating CAB/RPV-LA in participants with a history of sub-optimal adherence and control of their HIV
NCT04518228	PK properties of ARV and TB drugs (including CAB-LA) administered during pregnancy and postpartum
NCT05154747	LATA (Long-Acting Treatment in Adolescents)—Randomized, open-label trial of CAB/RPV-LA in virologically suppressed HIV-1-positive adolescents aged 12–19 y
Implementation Trials
NCT03856580	Alternative CAB-LA injection strategies in transgender women evaluating self-injection and injection by a healthcare provider at “drop-in clinics”
NCT04001803	Qualitative Hybrid III implementation study to identify and evaluate strategies for successful implementation of CAB/RPV-LA
NCT04399551	Hybrid type III trial evaluating implementation strategies through continuous quality improvement for CAB/RPV-LA
NCT04863261	Scheduling CAB/RPV-LA alerts in the retention & huddle modules of the CHORUS App
NCT04973254	Hybrid implementation-effectiveness study evaluating CAB/RPV-LA administration outside of the standard doctor's office/clinic in community partner spaces
NCT04982445	GLACIER (Giving Long Acting CABENUVA in an Infusion centER)—Administration of CAB/RPV-LA in infusion centers

Abbreviations: ARV, antiretroviral; CAB-LA, long-acting cabotegravir; HIV, human immunodeficiency virus; IM, intramuscular; RPV-LA, long-acting rilpivirine; SC, subcutaneous; TB, tuberculosis.

^a www.clinicaltrials.gov.